Global Statistics Representing Fragment-Based Drug Discovery Market Scenario
Fragment-based drug discovery is the process of identifying and developing new drugs for several diseases. Fragment-based drug discovery starts with the identification of small fragment molecules which are about half size of typical drugs molecule. Later, these fragments are then optimized and interacts together to develop drug leads.
Continuous development in ‘In Silico’ methodology is driving the global fragment-based drug discovery market. The term ‘in silico’ is derived from the computer component silicium and is referred to the computational approach adopted in the drug development process. In silico methods play an important role in the fragment-based drug discovery design by supporting the identification of suitable fragments. The fragment-based approach involves the discovery of low-molecular-mass molecules. Once their interaction with the biological target molecules is clearly understood and experimentally validated, low-molecular-mass molecules signify a unique opportunity to develop potent and efficient larger compounds. In silico methods aids this whole procedure that enhance the speed and increase cost-effectiveness of the drug discovery. From the past few years, in silico methodology has been witnessing a continuous development in computational methods and aggressive launching of new computed products by companies. For instance, in June 2018, Bruker announced the scimaX MRMS resolution that would help biopharma users to perform advanced native protein and fragment-based drug discovery studies.
Increasing research activities on rare diseases is expected to support the market growth around the globe. Rare diseases are defined differently in several geographies; for instance, in the U.S., a disease that affects less than 200,000 people is considered a rare disease, whereas, in the European Union, it is defined as a disease that affects one in 2,000 people. Currently, more than 7000 rare diseases are identified across the globe, and only a fraction of them have approved treatments and therapies. Many leading pharmaceutical companies, government bodies, non-profit organizations, and policymakers are aggressively engaged in research and development activities to discover the efficient therapies to treat rare diseases.
Global fragment-based drug discovery market was valued at USD 644.2 million in 2018 and is expected to attain USD 1541.1 million by 2026, at a CAGR of 13.3%.
Global fragment-based drug discovery market is segmented into service component, end user, and region.
Based on service component, the market is segmented into fragment screening and fragment optimization. Fragment screening is further segmented into biophysical techniques and non-biophysical techniques. Biophysical techniques are segregated into NMR spectroscopy, DSF assay, fluorescence polarization (FP), isothermal titration calorimetry (ITC),X-ray crystallography, surface plasmon resonance, mass spectrometry, capillary electrophoresis, and other biophysical techniques. Fragment-based screening has emerged as a promising tool in the drug discovery process. Fragment-based drug design deals with the molecules having lower molecular weight ranging from100 and 300 Daltons and relatively limited functionality as compared to the larger molecules. The fragments possess affinities from the micromolar to the millimolar range, and hence the sensitive detection methods are required to identify such weak protein-ligands. Several biophysical techniques are available in the market to detect weak protein-ligand interactions such as nuclear magnetic resonance (NMR) spectroscopy and X-ray crystallography. However, different biophysical techniques can be used with combinations to identify suitable hit compounds.
Computational screening tools are non-biophysical techniques and play an important role in the fragment-based drug discovery. Several computational tools are developed, accepted, and adopted by researchers, industries, and various regulatory bodies. These computational methods are useful when combined with the experimental approaches. These are fast, cost-efficient methods compatible with a wide array of biological targets. Computational methods allow the researchers to bypass the random screening of molecules across hundreds of biological targets.
Fragment optimization is one the most important steps in the fragment-based drug discovery design. Fragment-based drug discovery starts with the recognition of fragments through screening. The inadequate quality of leads emanating from screening require extensive optimization to develop drug-like properties further and to generate potential lead compounds. Fragments are screened and optimized through experimental approaches and computational methods.
Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and the Middle East & Africa.
North America dominates the global fragment-based drug discovery market. High spending on research and development and presence of large pharmaceutical companies in the region, are the vital factors driving the market. North America is further segmented into the U.S., Canada, and Mexico. The U.S. is expected to dominate the regional fragment-based drug discovery market owing to the well-developed healthcare infrastructure and presence of many CROs and companies operating in the market including Abbott Laboratories. In the U.S., FDA’s Center for Drug Evaluation and Research (CDER) plays a key role in the evaluation of new drugs before they can be sold. A team of CDER comprised of physicians, statisticians, chemists, pharmacologists, and other scientists which reviews the drugs and test it whether the drug is safe and effective for its intended use. Drug approval process in the U.S. is done through a structural framework, which includes following steps: analysis of the target condition and available treatments, assessment of benefits and risks from clinical data, and strategies for managing risks.
Europe is expected to witness significant growth in the global fragment-based drug discovery market during the forecast period 2019–2026 owing to the access to advanced technology, rising adoption of fragment-based drug discovery in academic level research, and cumulative efforts for R&D activities from several developed countries through European Union. Europe is sub-segmented into Germany, France, the U.K, Italy, Spain, and the rest of Europe. In the European region, Germany is expected to dominate the regional fragment-based drug discovery market owing to the dense network of good to an excellent university and non-university research facilities and existence of many member companies of Association of Research-Based Pharmaceutical Companies. European Union has synchronized R&D efforts of all member countries and formed the European Medicines Agency for evaluation of medicinal products. EMA is supported by thousands of experts drawn from Europe, which allows the best possible scientific expertise for the regulation of medicines. EMA has framed evaluation procedure in following steps: Pre-submission, evaluation, and post-authorization.
Some of the major players in the fragment-based drug discovery market are, Astex Pharmaceuticals, Beactica AB, Charles River Laboratories International, Inc, Crown Bioscience, Inc., Evotec A.G, Kinetic Discovery Limited, Plexxikon Inc., Proteros Fragments GmbH, Sprint Bioscience, and Structure Based Design, Inc.
Fragment-Based Drug Discovery Market Segmentation
By Service Component
By End User
Frequently Asked Questions (FAQs)